Moderna (MRNA) financial statements
+1693.4%since 2016
- FY2025 revenue
- $1.9B▼ −39.9%
- FY2025 net income
- −$2.8B
- FY2025 diluted EPS
- −$7.26
- FY2025 free cash flow
- −$2.1B
Moderna income statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 1,944 | 3,236 | 6,848 |
| Operating income | -3,074 | -3,945 | -4,239 |
| Pretax income | -2,768 | -3,607 | -3,942 |
| Net income | -2,822 | -3,561 | -4,714 |
| Diluted earnings per share | -7.26 | -9.28 | -12.33 |
Moderna balance sheet
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents (derived) | 2,595 | 1,929 | 2,907 |
| Total assets | 12,338 | 14,142 | 18,426 |
| Total liabilities | 3,688 | 3,241 | 4,572 |
| Total equity | 8,650 | 10,901 | 13,854 |
| Long-term debt | 590 | 0 | n/a |
Moderna cash flow statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | -1,873 | -3,004 | -3,118 |
| Capital expenditure | -192 | -1,051 | -707 |
| Free cash flow (derived) | -2,065 | -4,055 | -3,825 |
| Share repurchases | -2 | 0 | -1,153 |
Quarterly highlights
| USD millions | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 |
| Revenue (derived) | 1,313 | 145 | 389 | 678 |
| Operating income (derived) | 130 | -815 | -1,388 | -857 |
| Net income (derived) | 162 | -782 | -1,343 | -826 |
| Diluted earnings per share | 0.38 | -1.97 | -3.40 | n/a |
| Operating cash flow (derived) | -1,559 | -526 | -630 | 930 |
| Total assets | 13,468 | 10,961 | 11,488 | 12,338 |
Moderna major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| Abigail P. Johnson | 14.8% | 58,929,948 | 5 November 2026 |
| FMR LLC | 14.8% | 58,929,948 | 5 November 2026 |
| Vanguard Capital Management | 6.5% | 25,933,824 | 30 April 2026 |
| Capital World Investors | 5.6% | 22,276,996 | 13 August 2026 |
Moderna 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 16 November 2026 | 8-K | Current report | Current report |
| 13 November 2026 | 8-K | Current report | Current report |
| 6 November 2026 | 10-Q | Quarterly report | Quarterly report |
| 6 November 2026 | 8-K | Current report | Current report |
| 30 September 2026 | 8-K | Current report | Current report |
| 1 September 2026 | 8-K | Current report | Current report |
| 31 July 2026 | 10-Q | Quarterly report | Quarterly report |
| 31 July 2026 | 8-K | Current report | Current report |
Common questions
What was Moderna's revenue in fiscal 2025?
Moderna reported $1.9 billion in revenue for fiscal 2025, the year ended 31 December 2025, down 39.9% from fiscal 2024.
What was Moderna's net income in fiscal 2025?
Moderna reported a net loss of $2.8 billion for fiscal 2025, the year ended 31 December 2025. Diluted earnings per share were −$7.26.
What was Moderna's free cash flow in fiscal 2025?
Moderna had negative free cash flow of $2.1 billion in fiscal 2025. Operating cash flow was -$1.9 billion and capital expenditure was $192 million.
What were Moderna's total assets at the end of fiscal 2025?
Moderna reported total assets of $12.3 billion at the end of fiscal 2025, the year ended 31 December 2025.
How much Moderna history do I get?
Every account gets the full history, annual and quarterly, with first reported values and as of dates.
Start with a free key
Free $10 credits every month, no card.Free $10 credits a month, no card.